Topical Tranexamic Acid Serum, graded Moderate-evidence on Magellan — trials are short and heterogeneous, melasma often relapses after stopping, and benefits beyond pigmentation (general anti-aging claims) are extrapolation. Studied dose: 2-5% topical cream or serum, typically for 8-12 weeks. Magellan links 18 peer-reviewed citations for Topical Tranexamic Acid Serum.
Source: J Cosmet Dermatol 2023, PMID 36606378 ↗ · Skin & Topical Longevity · How Magellan grades evidence · Study write-up · evidence confidence: high
Topical tranexamic acid (TXA; trans-4-aminomethylcyclohexanecarboxylic acid) is a synthetic lysine derivative originally developed as an oral antifibrinolytic (plasmin inhibitor) to reduce bleeding, later found to lighten ultraviolet- and hormone-driven facial hyperpigmentation such as melasma. Applied to the skin it interferes with the plasminogen-plasmin pathway in keratinocytes, dampening UV-induced prostaglandin and arachidonic-acid signaling to melanocytes and thereby reducing melanocyte tyrosinase activity and melanin production without decreasing the number of melanocytes. It is formulated as a serum or cream, typically at concentrations of 2-5%, for melasma and other facial dyschromia.
In randomized controlled trials and multiple meta-analyses, topical tranexamic acid significantly lowers melasma severity scores (MASI/mMASI and melanin index) and performs comparably to the long-standing standard agent hydroquinone, frequently with fewer irritant side effects; combining it with microneedling or laser-assisted delivery can add further benefit. Honest limitations: many trials are small, short (typically 8-12 weeks) and heterogeneous, melasma tends to relapse after treatment stops, and pooled analyses indicate oral TXA is more potent than the topical form, though the oral route carries clotting-risk contraindications that minimally absorbed topical use largely avoids. The evidence is specific to melasma and hyperpigmentation; broader anti-aging claims are extrapolation. This evidence concerns the compound tranexamic acid and its mechanism and formulations, not this specific commercial serum product.
Peer-reviewed studies on the active compound — citations link to PubMed.
“topical tranexamic acid can improve outcomes and is better tolerated than hydroquinone”
“tranexamic acid is a new and promising drug for the treatment of melasma”
“combining topical tranexamic acid and laser therapy is an effective and safer treatment for melasma”
“TXA significantly reduced melasma severity, evidenced by reductions in MASI, mMASI, MI, and hemi-MASI scores. Oral TXA showed the most substantial decrease in MASI scores, followed by injections and topical applications.”
“Pooled data from tranexamic acid-only observational studies with pre- and post-treatment Melasma Area and Severity Index (MASI) showed a decrease of 1.60 in MASI (95% confidence interval (CI), 1.20-2.00; p<0.001)”
“The combined results showed that the use of TA was associated with reduced Melasma Area and Severity Index (MASI) and Melanin Index (MI). No significant difference in Erythema Index (EI) was observed with TA treatment.”
Research describes the active mechanism and is not a claim about this specific product.
Randomized, mostly split-face trials indicate that topical niacinamide can modestly…
Randomized and controlled human trials, together with histologic and in vitro studies,…
In a randomized community-based trial in Australia, adults assigned to daily sunscreen…
Multiple randomized and controlled clinical studies of topical HA formulations report…
Yes — its active compound is linked to 18 peer-reviewed studies, summarized and cited above.
You can buy it on Amazon via the link above; Magellan earns a small affiliate commission at no extra cost to you, which does not affect the evidence grade.
Dietary supplements and devices are generally well tolerated but are not a substitute for medical care. Talk to your physician before starting, especially if you take medication or have a health condition.